Electrolyte abnormalities with zoledronic acid therapy.
Steven M
SM
Sorscher
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary*; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced; D017674:Hypophosphatemia / Q000139:chemically induced; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D008274:Magnesium / Q000097:blood; D000077268:Pamidronate; D000077211:Zoledronic Acid
D000970:Antineoplastic Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D008274:Magnesium; D000077268:Pamidronate